Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Rhea-AI Summary

Nascent Biotech has announced a partnership with BioTools, focusing on the monoclonal antibody Pritumumab (PTB), aimed at treating brain cancer. This collaboration leverages BioTools' advanced ROA laser-based technology to enhance the characterization of PTB's higher-order molecular structure, potentially improving its effectiveness and applications. PTB, currently in Phase I clinical trials, is expected to benefit from BioTools' expertise in biologic characterization, aiding in the optimization of its pharmaceutical properties.

Positive

• Partnership with BioTools may enhance PTB's effectiveness.
• Utilization of advanced ROA technology for detailed molecular structure analysis.
• PTB is currently in Phase I clinical trials for brain cancer treatment.

Negative

• Products not yet commercially available.

VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS).

Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification.

PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding ("secondary structure") and the more extensive, 3-dimensional results ("tertiary structure") have dramatic impact on the molecule's pharmaceutical effectiveness.

"BioTools is known worldwide for their knowledge and expertise in the field of Raman, ROA, and biologic FTIR. We are very pleased to have had an opportunity to work with their scientists to deliver this refined capability for our monoclonal antibody (mAb) development platform."-Sean Carrick, CEO, Nascent Biotech Inc.

"Nascent's mAb PTB is an ideal match for our instrumentation as well as for our vision of expanding Raman/ROA+FTIR to more widespread, routine use in BioPharma research labs. This suite of techniques, coupled with the accompanying BioTools' databases and software, have powerful application to the characterization of higher order structures for many therapeutics."-BioTools, President & Co-Founder, Dr. Rina Dukor

About Nascent Biotech:

Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers helping millions of people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer at Sharp Healthcare and Hoag Presbyterian Hospital.

About BioTools:

BioTools is a life sciences tools company that revolutionized characterization technology for the most important therapeutics of our time - chiral small molecules and biologics. The breakthrough analytical techniques developed by the company provide molecular structure information which governs safety and efficacy - analyzed in a fraction of a time compared to traditional methodology. BioTools product offerings include instrumentation, specialized CRO services, and unique software and accessories. The products are used globally by most of the world's top 100 pharmaceutical companies, renowned academic institutions, and government laboratories, including the US Food & Drug Administration (FDA). Founded in 2000, BioTools has R&D, sales, customer support, contract research lab and manufacturing facilities in Jupiter, Florida, and two international divisions, BioTools Europe, headquartered in the United Kingdom, and BioTools China, headquartered in Dalian. BioTools' co-founders and products have been recognized by numerous International Awards, including the R&D 100 Top Innovation Award. For more information, visit https://biotools.us/ or contact us at info@biotools.us. Follow us on LinkedIn and Twitter

For further information, contact:

Sean Carrick, President | CEO, Nascent Biotech
E: sean.carrick@nascentbiotech.com
W: www.nascentbiotech.com
P: 772.713.0541

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/696930/Nascent-Biotech-and-BioTools-Partner-in-the-Fight-Against-Cancer-Using-ROA-to-Define-the-Higher-Order-Structure-of-PTB-a-Unique-Monoclonal-Antibody

FAQ

What is the partnership between Nascent Biotech and BioTools about?

The partnership focuses on enhancing the monoclonal antibody Pritumumab (PTB) for brain cancer treatment using BioTools' advanced analytical technology.

What technology is BioTools providing to Nascent Biotech?

BioTools offers ROA laser-based technology for detailed characterization of PTB's higher-order molecular structure.

Where is Pritumumab (PTB) currently in its clinical trials?

PTB is undergoing Phase I clinical trials at Sharp Healthcare and Hoag Presbyterian Hospital.

What is the current status of Pritumumab's availability?

Pritumumab (PTB) is not yet commercially available as it is still in clinical trials.

What is Nascent Biotech's focus in developing Pritumumab?

Nascent Biotech is focused on developing Pritumumab as a treatment for brain cancer.